Sciverse Solutions, an AI-first point-of-care testing (PoCT) diagnostics company, has announced a strategic collaboration with Bhat Biotech, a biotechnology and molecular diagnostics company. The partnership aims to co-develop next-generation molecular diagnostic platforms to support faster and accessible testing at the point of care.
The collaboration will combine Sciverse’s expertise in AI, biosensors, microfluidics, and hardware design with Bhat Biotech’s experience in molecular assay development and manufacturing. Both organisations plan to accelerate the development of portable diagnostic systems capable of providing high-accuracy test results in real time at patient care sites.
“Molecular diagnostics is shaping the future of healthcare — enabling faster, more precise, and accessible disease detection,” said Rahul Singh, Managing Director of Sciverse Solutions Pvt. Ltd. “Our collaboration with Bhat Biotech reflects a shared commitment to redefining how molecular testing can be brought closer to patients, doctors, and healthcare workers everywhere.”
Dr Shama Bhat, Founder of Bhat Biotech, said, “By integrating Bhat Biotech’s assay chemistry expertise with Sciverse’s device and AI capabilities, we are confident this collaboration will lead to molecular platforms that are more robust, cost-effective, and scalable across global markets.”
Pavan Kumar, Managing Director of Bhat Biotech, added, “This partnership is a natural alignment of strengths. Bhat Biotech’s legacy in molecular innovation and Sciverse’s engineering depth create a strong foundation for building the next era of diagnostic technologies. We look forward to creating solutions that will truly impact healthcare access and quality.”